Gilead Sciences Inc. (GILD)

Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment

Swiss approve insurance cover for Novartis, Gilead cell therapies

Peninsula company lands expert to marry data with drug discovery

China Negotiates Bargain Prices With Big Pharma

Here is What Hedge Funds Think About Gilead Sciences, Inc. (GILD)

5 Top Stock Trades for Tuesday: NVDA, TSLA, GILD